Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

‘Dangling’ Cancer Indications In US: New Year Brings New Withdrawals Of Accelerated Approvals

Jan 19 2022

• By Sue Sutter

Jenga block removal — FDA scrutiny has led to removal of accelerated approval cancer indications. • Source: Alamy

Related Content

Accelerated Approval: US FDA Review Of Expedited Program Could Bring More Withdrawals

Feb 24 2021

‘Dangling’ Accelerated Approvals: US FDA Flags Concerns About ‘Marginal’ Response Rates

Apr 22 2021

Keeping Track: US FDA Clears On Target’s Cytalux, VBI’s PreHevbrio; Keytruda Grows In Adjuvant Melanoma

Dec 04 2021

Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA

Oct 01 2018

Zydelig Takes Major Hit, But Not A Big Blow For Gilead

Mar 15 2016

Gilead Doesn’t Push Limits In Pricing Its New Lymphoma Drug <em>Zydelig</em>

Jul 23 2014

US FDA Cancels Panel Review Of Two ‘Delinquent’ Cancer Drug Accelerated Approvals

Nov 30 2021

Infinity Doesn't Sugarcoat Disappointing Duvelisib Data; Cuts R&D Staff To Preserve Cash

Jun 15 2016

Related Companies

Gilead Sciences, Inc.

Secura Bio, Inc.

Verastem, Inc.

Infinity Pharmaceuticals, Inc.

Acrotech Biopharma LLC

Additional Topics

United States Clinical Trials Review Pathway Regulation Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.